Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure, plasma catecholamines, and left ventricular mass

American Journal of Cardiology

Volumn 78, Issue 2, 1996, Pages 203-207

  Leenen, Frans H H ^a,b   Fourney, Anne ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b HEART AND STROKE FOUNDATION OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMLODIPINE; AMLODIPINE BESYLATE; CALCIUM ANTAGONIST; CATECHOLAMINE; DILTIAZEM; NORADRENALIN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART INDEX; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SUSTAINED RELEASE PREPARATION; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE;

ADOLESCENT; ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CATECHOLAMINES; DILTIAZEM; FEMALE; HEART RATE; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; VENTRICULAR FUNCTION, LEFT;

EID: 0030054726     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)90396-3     Document Type: Article

References (22)

1. Leenen FHH, Harmsen E. Antihypertensive drugs and cardiac trophic mechanisms. J Cardiovasc Pharmacol 1991;17(suppl 2):S50-S57.
2. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992;6:85-90.
3. Leenen FHH, Holliwell DL. Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol 1992;69:639-645.
4. Leenen FHH, Fourney A, Notman G, Tanner J. Persistence of anti-hypertensive effect after "missed doses" of calcium-antagonist with long (amlodipine) versus short (diltiazem) elimination half life. Br J Clin Pharmacol 1996;41:83-88.
5. Sahn DJ, DeMaria A, Kisslo J, Weyman A. The Committee on M-mode Standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-1083.
6. Woythaler JN, Singer SL, Kwan OL, Meltzer RS, Reubner B, Bommer W, DeMaria A. Accuracy of echocardiography versus electrocardiography in detecting left ventricular hypertrophy: Comparison with postmortem mass measurements. J Am Col Cardiol 1983;2:305-311.
7. Sole MJ, Hussain MN. A simple and specific radioenzymatic assay for the simultaneous measurement of picogram quantities of norepinephrine, epinephrine and dopamine in plasma and tissues. Biochem Med 1977;18:301-307.
8. Ruzicka M, Leenen FHH. Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists. In Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management. 2nd edition New York:Raven Press, 1995:2815-2825.
9. Ruzicka M, Leenen FHH. Relevance of 24 hour blood pressure profile and sympathetic activity for outcome on short- vs long-acting 1,4-dihydropyridines. Am J Hypertension 1996;9:86-94.
10. Yusuf S, Held PH, Furberg CD. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991;67:1295-1297.
11. Julius S. Sympathetic hyperactivity and coronary risk in hypertension. Hypertension 1993;21:886-893.
12. Bainbridge AD, Herlihy O, Meredith PA, Elliott HL. A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices. Eur J Clin Pharmacol 1993;45:425-430.
13. Millard RW, Grupp G, Grupp IL, DiSalvo J, DePover A, Schwartz A. Chronotropic, inotropic, and vasodilator actions of diltiazem, nifedipine and verapamil. Circ Res 1983;52(suppl I);29-39.
14. Klein W, Brandt D, Vrecko K, Harringer M. Role of calcium antagonists in the treatment of essential hypertension. Circ Res 1983;52 (suppl I);174-181.
15. Safar ME, Simon ACh, Levenson JA, Cazor JL. Hemodynamic effects of diltiazem in hypertension. Circ Res 1983;52(suppl I);169-173.
16. Inouye IK, Massie BM, Benowitz N, Simpson P, Loge D. Antihypertensive therapy with diltiazem and comparison with hydrochlorothiazide. Am J Cardiol 1984;53:1588-1592.
17. Schmieder RE, Messerli FH, Garavaglia GE, Nunez BDI. Cardiovascular effects of verapamil in patients with essential hypertension. Circulation 1987;75:1030-1036.
18. Kailasam MT, Parmer RJ, Cervenka JH, Wu RA, Ziegler MG, Kennedy BP, Adegbile IA, O'Connor DT. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomie function in human hypertension. Hypertension 1995;26:143-149.
19. Tsoporis J, Fields N, Leenen FHH. Contrasting effects of calcium antagonists vs arterial vasodilators on cardiac anatomy and sympathetic activity in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1991;17(suppl 2):S166-S168.
20. Kushiro T, Asagami T, Takahashi A, Furukawa LN, Saitoh F, Hino T. Kurumatani H, Otsuka Y, Osada T, Kajiwara N, Kanmatsuse K. Effects of long acting calcium channel blocker (CCB) and hydralazine on insulin sensitivity in spontaneously hypertensive rats (SHR). Am J Hypertens 1995;8:72A.
21. Fields N, Tsoporis J, Leenen FHH. Differential effects of the calcium antagonist, nisoldipine, versus the arterial vasodilator, minoxidil. on ventricular anatomy, intravascular volume, and sympathetic activity in rats. J Cardiovasc Pharmacol 1989;14:826-835.
22. Higuchi S, Takeshita A, Ito N, Imaizumi T, Matsuguchi H, Nakamura M. Arterial pressure and heart rate responses to calcium channel blockers administered in the brainstem in rats. Circ Res 1985;57:244-251.